Related Experiment Video
Updated: May 22, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography
Published on: June 7, 2013
The kinin system in hypertensive pathophysiology
1Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Health Sciences Center, Kuwait University, P.O. Box 24923, 13110, Safat, Kuwait. j.n.sharma@hsc.edu.kw
Insights
The kallikrein-kinin system plays a key role in cardiovascular health. Reduced activity of this system is linked to cardiovascular diseases, but enhancing it shows therapeutic promise.
Area of Science:
- Cardiovascular Physiology and Pharmacology
- Molecular Medicine
Background:
- Cardiovascular diseases (CVDs) are the leading global cause of mortality.
- The kallikrein-kinin system (KKS) is implicated in vascular smooth muscle and cardiac function.
- Reduced KKS activity is associated with various cardiovascular conditions including hypertension, ischemia, and hypertrophy.
Purpose of the Study:
- To explore the role of the kallikrein-kinin system in cardiovascular pathophysiology.
- To investigate the therapeutic potential of modulating the KKS for cardiovascular and renal diseases.
Main Methods:
- Review of clinical and experimental data linking KKS activity to disease states.
- Analysis of the mechanisms underlying the cardioprotective effects of angiotensin-converting enzyme inhibitors.
- Evaluation of kallikrein gene delivery and kinin agonists as potential therapies.
Main Results:
- Evidence suggests reduced KKS activity contributes to cardiovascular disease development.
- Angiotensin-converting enzyme inhibitors' benefits are partly mediated by preserving kinin-forming components.
- Kallikrein gene delivery demonstrates a broad range of beneficial effects.
Conclusions:
- Restoring or enhancing kallikrein-kinin system activity holds significant therapeutic potential for hypertension, cardiovascular, and renal diseases.
- Kallikrein gene therapy and future kinin agonists represent promising strategies for managing these conditions.
Abstract:
Cardiovascular diseases are the prime cause of death in the world. The kallikrein-kinin system has been implicated in the pathophysiology of the vascular smooth muscle and cardiac dysfunctions. In recent years, numerous observations obtained from clinical and experimental models of diabetes, hypertension, cardiac failure, ischemia, myocardial infarction and left ventricular hypertrophy, have suggested that the reduced activity of the local kallikrein-kinin system may be instrumental for the induction of cardiovascular-related diseases. The cardioprotective actions of the angiotensin-converting enzyme inhibitors are primarily dependent on protecting the kinin-forming components, which may cause regression of the left ventricular hypertrophy in hypertensive situations. The ability of kallikrein gene delivery to produce a wide spectrum of beneficial effects makes it an excellent candidate in treating hypertension, cardiovascular and renal diseases. In addition, stable kinin agonists may also be available in the future as therapeutic agents for cardiovascular and renal disorders.
Related Concept Videos
Hypertension II: Pathophysiology
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Hypertension and Regulation of Blood Pressure
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Action of β1 Blockers
Heart Failure II: Pathophysiology

